Westhampton Capital LLC acquired a new stake in Celgene Co. (NASDAQ:CELG) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 4,990 shares of the biopharmaceutical company’s stock, valued at approximately $461,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Archford Capital Strategies LLC raised its position in shares of Celgene by 277.8% during the first quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 200 shares during the last quarter. Liberty Wealth Management LLC raised its position in shares of Celgene by 212.8% during the second quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 200 shares during the last quarter. Investors Research Corp bought a new stake in shares of Celgene during the first quarter worth $28,000. Weaver Consulting Group bought a new stake in shares of Celgene during the first quarter worth $29,000. Finally, Alera Investment Advisors LLC raised its position in shares of Celgene by 109.9% during the first quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 167 shares during the last quarter. Institutional investors own 74.04% of the company’s stock.
NASDAQ:CELG traded down $1.01 on Friday, reaching $94.70. The company’s stock had a trading volume of 2,059,854 shares, compared to its average volume of 3,633,113. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $98.97. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.32 and a current ratio of 3.44. The firm has a market cap of $67.83 billion, a PE ratio of 12.44, a PEG ratio of 0.44 and a beta of 1.46. The business’s 50-day moving average price is $93.08 and its two-hundred day moving average price is $92.64.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.17. The company had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.22 billion. Celgene had a return on equity of 89.93% and a net margin of 32.24%. Celgene’s revenue for the quarter was up 15.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.16 earnings per share. As a group, sell-side analysts expect that Celgene Co. will post 9.96 EPS for the current year.
A number of equities research analysts have recently weighed in on the company. Mizuho downgraded Celgene from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $103.00 to $100.00 in a research report on Monday. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 3rd. Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a research note on Tuesday, July 23rd. Cowen reaffirmed a “hold” rating and set a $102.00 price objective on shares of Celgene in a research note on Tuesday, July 30th. Finally, ValuEngine cut Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Two analysts have rated the stock with a sell rating, seventeen have issued a hold rating and three have assigned a buy rating to the company. Celgene has an average rating of “Hold” and a consensus price target of $94.60.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: Intrinsic Value
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.